You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

EGFR p.T790M-positive

Showing 1 - 25 of >10,000
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Bronchial Tumors Trial in Germany, Spain (EGF816, Trametinib)

Recruiting
  • Bronchial Neoplasms
  • Cologne, Germany
  • +6 more
Nov 2, 2022

Lung Cancer Stage IV, EGFR T790M Trial in Seoul (Lazertinib)

Not yet recruiting
  • Lung Cancer Stage IV
  • EGFR T790M
  • Seoul, MA, Korea, Republic of
    Samsung Medical Center
Jan 26, 2023

Osimertinib for Russian EGFR T790M Mutation-positive NSCLC

Recruiting
  • Non Small Cell Lung Cancer
  • +2 more
    • Moscow, Russian Federation
      Federal State Budgetary Institution National Medical Research Ce
    Mar 29, 2022

    EGFR T790M, Osimertinib, NSCLC Trial in Beijing (Osimertinib)

    Recruiting
    • EGFR T790M
    • +3 more
    • Beijing, Beijing, China
      Junling Li
    Jul 21, 2022

    Lung Cancer Trial in Boston, Nashville

    Active, not recruiting
    • Lung Cancer
      • Boston, Massachusetts
      • +1 more
      Dec 28, 2022

      Non Small Cell Lung Cancer Trial in Worldwide (AZD9291)

      Active, not recruiting
      Has Results
      • Non Small Cell Lung Cancer
      • La Jolla, California
      • +43 more
      Nov 25, 2022

      Metastatic Lung Non-Small Cell Carcinoma, EGFR T790M Trial in Seoul (Lazertinib)

      Not yet recruiting
      • Metastatic Lung Non-Small Cell Carcinoma
      • EGFR T790M
      • Seoul, Korea, Republic of
        Samsung Medical Center
      May 18, 2022

      NSCLC, EGFR Sensitive Mutation, Adjuvant Therapy Trial in Beijing, Nanjing, Shanghai (Befotertinib + Icotinib , Icotinib +

      Recruiting
      • Non-Small Cell Lung Cancer
      • +2 more
      • Befotertinib + Icotinib placebo
      • Icotinib + Befotertinib placebo
      • Beijing, China
      • +2 more
      Sep 20, 2023

      Lung Cancer Trial (Lazertinib 240 mg)

      Approved for marketing
      • Lung Cancer
      • Lazertinib 240 mg
      • (no location specified)
      Feb 15, 2022

      NSCLC With EGFR T790M Mutation, With Brain and/or Leptomeningeal Metastasis, Failed Tyrosine Kinase Inhibitors Trial in Seoul

      Active, not recruiting
      • Non-Small Cell Lung Cancer With EGFR T790M Mutation
      • +2 more
      • Seoul, Korea, Republic of
        Department of Medicine, Samsung Medical Center, Sungkyunkwan Uni
      Aug 8, 2021

      NSCLC Trial (Chemotherapy, Alflutinib plus chemo)

      Not yet recruiting
      • NSCLC
      • (no location specified)
      Jan 25, 2022

      NSCLC Trial in Beijing, Nanjing, Suzhou (BPI-7711 Capsule)

      Completed
      • Non-small Cell Lung Cancer
      • BPI-7711 Capsule
      • Beijing, Beijing, China
      • +3 more
      May 13, 2022

      Osimertinib for HK Chinese With Metastatic T790M Mutated

      Completed
      • Non-small Cell Lung Cancer
      • Hong Kong, China
      • +3 more
      Sep 7, 2021

      NSCLC Trial in Japan, Korea, Republic of, Singapore (capmatinib, pemetrexed, cisplatin)

      Terminated
      • Carcinoma, Non-Small-Cell Lung
      • Kashiwa, Chiba, Japan
      • +3 more
      Jan 31, 2023

      Either EML4-ALK Gene Rearrangements or T790M EGFR Mutation in

      Active, not recruiting
      • Carcinoma, Non-Small-Cell Lung
        • Hollywood, Florida
        • +1 more
        Sep 29, 2021

        Osimertinib in Advanced Non-Small Cell Lung Cancer EGFR-T790M

        Completed
        • Non Small Cell Lung Cancer
        • Oviedo, Asturias, Spain
        • +30 more
        Jun 1, 2022

        Lung Tumors, EGFR Gene Mutations Trial in Hwasun (Osimertinib)

        Completed
        • Lung Neoplasms
        • EGFR Gene Mutations
        • Hwasun, Jeonnam, Korea, Republic of
          Chonnam National University Hwasun Hospital
        Aug 1, 2021

        Metastatic NSCLC Trial in China (AC0010)

        Active, not recruiting
        • Metastatic Non-small Cell Lung Cancer
        • Beijing, Beijing, China
        • +16 more
        Sep 2, 2021

        Lazertinib Dose Modification on Effectiveness and Safety

        Not yet recruiting
        • Non-small Cell Lung Cancer
        • Busan, Korea, Republic of
        • +10 more
        Jan 29, 2023

        NSCLC Trial in Spain (Osimertinib)

        Completed
        • Non-Small Cell Lung Cancer
        • Barcelona, Spain
        • +6 more
        Nov 25, 2020

        Non Small Cell Lung Cancer (NSCLC) Trial in India (Osimertinib)

        Completed
        Has Results
        • Non Small Cell Lung Cancer (NSCLC)
        • Hyderabad, India
        • +6 more
        May 10, 2021

        Lung Tumors, NSCLC, Respiratory Tract Tumors Trial in Worldwide (BLU-945, osimertinib)

        Recruiting
        • Lung Neoplasms
        • +23 more
        • La Jolla, California
        • +35 more
        Oct 6, 2022

        Clinical Stage I HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Clinical Stage II HPV-Mediated (p16-Positive)

        Recruiting
        • Clinical Stage I HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8
        • +10 more
        • Intensity-Modulated Radiation Therapy
        • +4 more
        • Houston, Texas
          M D Anderson Cancer Center
        Nov 8, 2022

        AZD9291 Treatment in T790M Positive Non-small Cell Lung Cancer

        Completed
        • Non Small Cell Lung Cancer
          • Kaohsiung, Taiwan
          • +6 more
          Dec 17, 2020

          NSCLC Trial (Furmonertinib)

          Not yet recruiting
          • Non-Small Cell Lung Cancer
          • (no location specified)
          Aug 10, 2023